Drawing for VANRAFIA

USPTO serial 79238110

VANRAFIA

Reviewed by CopyMark Law Group

Reg. 5640110Status 706Registered
Filing date
Status date
Registration date
Jan 1, 2019
Examiner
VO, JULIE
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with VANRAFIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609United States

Goods and services

ClassDescriptionStatusFirst use
005[ Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; ] pharmaceutical preparations for the prevention and treatment of kidney diseases [ ; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 21, 2026INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 21, 2025NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Aug 21, 202571AGREGISTERED-SEC.71 ACCEPTED—
Aug 11, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 16, 2025ES71TEAS SECTION 71 RECEIVED—
Aug 13, 2024RNWLINTERNATIONAL REGISTRATION RENEWED—
Apr 12, 2019GPNXNOTIFICATION PROCESSED BY IB—
Feb 8, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 8, 2019FIMPFINAL DISPOSITION PROCESSED—
Jan 31, 2019GPARGRANT OF PROTECTION CREATED, TO BE SENT TO IB—
Jan 1, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 9, 2018GPNXNOTIFICATION PROCESSED BY IB—
Oct 16, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 26, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 26, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Sep 26, 2018NPUBNOTICE OF PUBLICATION—
Sep 10, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 7, 2018DOCKASSIGNED TO EXAMINER—
Aug 14, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 8, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 3, 2018LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Aug 2, 2018SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance